P3-164: A phase II trial of pemetrexed(p) in patients (pts) with performance status (PS) 2 and 3 as 1st– and 2nd– line treatment for advanced non–small–cell lung cancer (NSCLC)
Zinner R, Fossella F, Kies M, Herbst R, Lu C, Johnson F, Price J, Cleeland C, Wang S. P3-164: A phase II trial of pemetrexed(p) in patients (pts) with performance status (PS) 2 and 3 as 1st– and 2nd– line treatment for advanced non–small–cell lung cancer (NSCLC). Journal Of Thoracic Oncology 2007, 2: s749. DOI: 10.1097/01.jto.0000284139.01895.99.Peer-Reviewed Original ResearchA phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced non-small cell lung cancer (NSCLC)
Zinner R, Fossella F, Kies M, Herbst R, Lu C, Johnson F, Bhat S, Price J, Cleeland C, Wang X. A phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2007, 25: 18149-18149. DOI: 10.1200/jco.2007.25.18_suppl.18149.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerResponse rateConstitutional toxicityStage IIIB/IV non-small cell lung cancerFatal pulmonary emboliPerformance status 2Promising response ratesSecond-line therapySecond-line treatmentLines of therapyPhase II trialPhase III trialsCell lung cancerFavorable safety profileSerial blood samplesPS 2Prior regimenStage IIIBII trialIII trialsMedian survivalPS 0Pulmonary emboliMedian age